4D Advisors LLC bought a new position in shares of GoHealth, Inc. (NASDAQ:GOCO - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 150,000 shares of the company's stock, valued at approximately $1,840,000. GoHealth makes up 1.4% of 4D Advisors LLC's investment portfolio, making the stock its 25th biggest holding. 4D Advisors LLC owned approximately 0.65% of GoHealth at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Cubist Systematic Strategies LLC lifted its position in shares of GoHealth by 297.3% in the first quarter. Cubist Systematic Strategies LLC now owns 10,915 shares of the company's stock valued at $134,000 after acquiring an additional 8,168 shares in the last quarter. Trexquant Investment LP acquired a new stake in GoHealth during the first quarter worth about $166,000. Russell Investments Group Ltd. grew its stake in shares of GoHealth by 77.3% in the first quarter. Russell Investments Group Ltd. now owns 37,366 shares of the company's stock valued at $458,000 after buying an additional 16,290 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in GoHealth in the first quarter valued at about $212,000. Finally, N.E.W. Advisory Services LLC purchased a new position in GoHealth in the first quarter valued at about $45,000. 24.21% of the stock is currently owned by hedge funds and other institutional investors.
GoHealth Price Performance
Shares of NASDAQ GOCO traded down $0.08 during mid-day trading on Friday, reaching $4.81. The company had a trading volume of 29,777 shares, compared to its average volume of 43,406. The company has a current ratio of 1.56, a quick ratio of 1.56 and a debt-to-equity ratio of 2.64. The stock has a market cap of $137.61 million, a PE ratio of -1.34 and a beta of 1.61. The company has a 50-day moving average price of $5.71 and a two-hundred day moving average price of $8.54. GoHealth, Inc. has a 1-year low of $4.72 and a 1-year high of $21.00.
GoHealth (NASDAQ:GOCO - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($1.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.60) by $1.37. The business had revenue of $94.05 million for the quarter, compared to analysts' expectations of $119.76 million. GoHealth had a negative return on equity of 8.74% and a negative net margin of 3.21%. On average, equities analysts anticipate that GoHealth, Inc. will post -5.5 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of brokerages recently commented on GOCO. Wall Street Zen downgraded GoHealth from a "hold" rating to a "sell" rating in a report on Friday, July 18th. Noble Financial reaffirmed an "outperform" rating on shares of GoHealth in a report on Friday, August 8th. Finally, Royal Bank Of Canada reduced their target price on GoHealth from $18.00 to $12.00 and set a "sector perform" rating on the stock in a report on Thursday, August 28th. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $12.00.
Check Out Our Latest Stock Analysis on GOCO
GoHealth Profile
(
Free Report)
GoHealth, Inc operates as a health insurance marketplace and Medicare-focused digital health company in the United States. The company operates a technology platform that leverages machine-learning algorithms of insurance behavioral data to optimize the process for helping individuals find the health insurance plan for their specific needs.
Further Reading

Before you consider GoHealth, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoHealth wasn't on the list.
While GoHealth currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.